Neoadjuvant for Liver Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Liver Cancer+1 MoreNeoadjuvant - CombinationProduct
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing two different treatments for people with a certain type of liver cancer. The first group of people will get a drug called Atezolizumab, and the second group will get a different drug called Bevacizumab. The trial will compare how well each treatment works.

Eligible Conditions
  • Liver Cancer
  • Portal Vein Tumour Thrombosis

Treatment Effectiveness

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: 2 years

17 Weeks
Hepatectomy
2 years
Response rate
Survival
Survival Progression Free
Toxicity to Atezolizumab/Bevacizumab
Toxicity to SBRT
90 days post operatively
Postoperative complications

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Neoadjuvant Atezolizumab/Bevacizumab
1 of 2
Neoadjuvant SBRT
1 of 2

Experimental Treatment

70 Total Participants · 2 Treatment Groups

Primary Treatment: Neoadjuvant · No Placebo Group · Phase 2

Neoadjuvant Atezolizumab/Bevacizumab
CombinationProduct
Experimental Group · 1 Intervention: Neoadjuvant · Intervention Types: CombinationProduct
Neoadjuvant SBRT
CombinationProduct
Experimental Group · 1 Intervention: Neoadjuvant · Intervention Types: CombinationProduct

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Hoffmann-La RocheIndustry Sponsor
2,360 Previous Clinical Trials
1,067,571 Total Patients Enrolled
4 Trials studying Liver Cancer
156 Patients Enrolled for Liver Cancer
Ontario Clinical Oncology Group (OCOG)Lead Sponsor
60 Previous Clinical Trials
20,593 Total Patients Enrolled
Jim Wright, MDStudy DirectorOCOG Director
3 Previous Clinical Trials
220 Total Patients Enrolled
Brandon Meyers, MDPrincipal Investigatorprinciple investigator

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
A lesion measuring 10 cm or less in maximum diameter on computed tomography (CT) or magnetic resonance imaging (MRI) is considered small.
Patients with Child-Pugh Class A cirrhosis, within 14 days prior to randomization, without any transfusions within 3 months, were included in the study.
, can often be successfully resected Solitary HCC without biliary invasion, or metastases, that has been proven through a biopsy can often be successfully resected.
PVTT involving the portal vein branches refers to a condition in which cancerous tumors develop in the branches of the portal vein